Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 19, Issue 12, 2013, Pages 1079-1083

  Van Dijk, Karin D ^a   Jongbloed, Wesley ^a,b   Heijst, Johannes A ^a   Teunissen, Charlotte E ^a   Groenewegen, Henk J ^a   Berendse, Henk W ^a   van de Berg, Wilma D J ^a   Veerhuis, Robert ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amyloid 42; Cerebrospinal fluid; Clusterin; Parkinson's disease; Plasma; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CLUSTERIN; PHOSPHOPROTEIN; PHOSPHORYLATED TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; STAGING; UNIFIED PARKINSON DISEASE RATING SCALE;

AMYLOID-Β-42; CEREBROSPINAL FLUID; CLUSTERIN; PARKINSON'S DISEASE; PLASMA; TAU;

CLUSTERIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84889085580     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.07.016     Document Type: Article

References (30)

1. Nuutinen T., Suuronen T., Kauppinen A., Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009, 61:89-104.
2. Poon S., Easterbrook-Smith S.B., Rybchyn M.S., Carver J.A., Wilson M.R. Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 2000, 39:15953-15960.
3. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
4. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41:1094-1099.
5. May P.C., Lampert-Etchells M., Johnson S.A., Poirier J., Masters J.N., Finch C.E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990, 5:831-839.
6. Nilselid A.M., Davidsson P., Nagga K., Andreasen N., Fredman P., Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int 2006, 48:718-728.
7. Schrijvers E.M., Koudstaal P.J., Hofman A., Breteler M.M. Plasma clusterin and the risk of Alzheimer disease. JAm Med Assoc 2011, 305:1322-1326.
8. Zhan S.S., Veerhuis R., Jansen I., Kamphorst W., Eikelenboom P. Immunohistochemical distribution of the inhibitors of the terminal complement complex in Alzheimer's disease. Neurodegeneration 1994, 3:111-117.
9. Gao J., Huang X., Park Y., Hollenbeck A., Chen H. An exploratory study on CLU, CR1 and PICALM and Parkinson disease. PLoS One 2011, 6:e24211.
10. Zhang X., Yin X., Yu H., Liu X., Yang F., Yao J., et al. Quantitative proteomic analysis of serum proteins in patients with Parkinson's disease using an isobaric tag for relative and absolute quantification labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. Analyst 2012, 137:490-495.
11. Maarouf C.L., Beach T.G., Adler C.H., Shill H.A., Sabbagh M.N., Wu T., et al. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol Res 2012, 34:669-676.
12. Yin G.N., Lee H.W., Cho J.Y., Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res 2009, 1265:158-170.
13. Lidstrom A.M., Hesse C., Rosengren L., Fredman P., Davidsson P., Blennow K. Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke. JAlzheimers Dis 2001, 3:435-442.
14. Přikrylová Vranová H., Mares J., Nevrly M., Stejskal D., Zapletalova J., Hlustik P., et al. CSF markers of neurodegeneration in Parkinson's disease. JNeural Transm 2010, 117:1177-1181.
15. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. JNeurol Neurosurg Psychiatr 1992, 55:181-184.
16. Roth M., Tym E., Mountjoy C.Q., Huppert F.A., Hendrie H., Verma S., et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986, 149:698-709.
17. Fahn S., Elton R.L. Unified Parkinson's disease rating scale. Recent development in Parkinson's disease 1987, 153-163. MacMillan Health Care Information, Florham Park, NJ. S. Fahn, C. Marsden, D. Calne (Eds.).
18. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
19. Lewis S.J., Foltynie T., Blackwell A.D., Robbins T.W., Owen A.M., Barker R.A. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. JNeurol Neurosurg Psychiatr 2005, 76:343-348.
20. Teunissen C.E., Petzold A., Bennett J.L., Berven F.S., Brundin L., Comabella M., et al. Aconsensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
21. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010, 67:739-748.
22. Murphy B.F., Kirszbaum L., Walker I.D., d'Apice A.J. SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. JClin Invest 1988, 81:1858-1864.
23. Mulder C., Verwey N.A., van der Flier W.M., Bouwman F.H., Kok A., van Elk E.J., et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010, 56:248-253.
24. van Dijk K.D., Teunissen C.E., Drukarch B., Jimenez C.R., Groenewegen H.J., Berendse H.W., et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis 2010, 39:229-241.
25. Jellinger K.A. CSF biomarkers in different phenotypes of Parkinson disease. JNeural Transm 2012, 119:455-456.
26. Prikrylova Vranova H., Mares J., Hlustik P., Nevrly M., Stejskal D., Zapletalova J., et al. Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease. JNeural Transm 2012, 119:353-362.
27. Polihronis M., Paizis K., Carter G., Sedal L., Murphy B. Elevation of human cerebrospinal fluid clusterin concentration is associated with acute neuropathology. JNeurol Sci 1993, 115:230-233.
28. Aasly J.O., Shi M., Sossi V., Stewart T., Johansen K.K., Wszolek Z.K., et al. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. Neurology 2012, 78:55-61.
29. Martin-Rehrmann M.D., Hoe H.S., Capuani E.M., Rebeck G.W. Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain. Neurotox Res 2005, 7:231-242.
30. Yasuhara O., Aimi Y., Yamada T., Matsuo A., McGeer E.G., McGeer P.L. Clusterin as a marker for ischaemic Purkinje cells in human brain. Neurodegeneration 1994, 3:325-329.